A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066

Graphical abstract

[1]  L. Pinna,et al.  Structural determinants of protein kinase CK2 regulation by autoinhibitory polymerization. , 2012, ACS chemical biology.

[2]  R. Battistutta,et al.  Active Form of the Protein Kinase CK2 alpha 2 beta 2 Holoenzyme Is a Strong Complex with Symmetric Architecture. , 2013 .

[3]  D. Fabbro,et al.  Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). , 2003, The Biochemical journal.

[4]  G. Unger,et al.  Protein kinase CK2--a key suppressor of apoptosis. , 2008, Advances in enzyme regulation.

[5]  Chris Abell,et al.  Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.

[6]  Adam Siddiqui-Jain,et al.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.

[7]  P. Colas,et al.  p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2 , 2006, Oncogene.

[8]  Yu-Wei Chang,et al.  An enriched structural kinase database to enable kinome‐wide structure‐based analyses and drug discovery , 2010, Protein science : a publication of the Protein Society.

[9]  K. Ahmed,et al.  Antisense oligonucleotides against protein kinase CK2‐α inhibit growth of squamous cell carcinoma of the head and neck in vitro , 2000, Head & neck.

[10]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[11]  L. Pinna,et al.  Unique Activation Mechanism of Protein Kinase CK2 , 2002, The Journal of Biological Chemistry.

[12]  Mark Whittaker,et al.  Picking up the pieces with FBDD or FADD: invest early for future success. , 2009, Drug discovery today.

[13]  R. Battistutta,et al.  Active form of the protein kinase CK2 α2β2 holoenzyme is a strong complex with symmetric architecture. , 2014, ACS chemical biology.

[14]  K. Ahmed,et al.  Intracellular Hydrogen Peroxide Production Is an Upstream Event in Apoptosis Induced by Down-Regulation of Casein Kinase 2 in Prostate Cancer Cells , 2006, Molecular Cancer Research.

[15]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[16]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[17]  Hans Matter,et al.  Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. , 2012, Angewandte Chemie.

[18]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[19]  O. Issinger,et al.  Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme , 2001, The EMBO journal.

[20]  C. Van Waes,et al.  Emergence of protein kinase CK2 as a key target in cancer therapy , 2010, BioFactors.

[21]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[22]  Y. Wong,et al.  Identification of chemical inhibitors of protein-kinase CK2 subunit interaction , 2008, Molecular and Cellular Biochemistry.

[23]  D. Gomez,et al.  Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice , 2008, International journal of cancer.

[24]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[25]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[26]  O. Issinger,et al.  Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.

[27]  O. Issinger,et al.  The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. , 2008, Chemistry & biology.

[28]  Caroline Barette,et al.  Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. , 2007, The Biochemical journal.

[29]  R. Prudent,et al.  New protein kinase CK2 inhibitors: jumping out of the catalytic box. , 2009, Chemistry & biology.

[30]  N. Birnberg,et al.  Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release. , 2015, Chemistry & biology.

[31]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[32]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.